2-氧代-2,3,4,5-四氢-1H-1-BENZ氮杂卓-7-磺酰氯 | 927869-56-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 2-氧代-2,3,4,5-四氢-1H-1-BENZ氮杂卓-7-磺酰氯
• 英文名称: 2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-7-sulfonyl chloride
• 英文别名: 2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-7-sulfonyl chloride；2-oxo-1,3,4,5-tetrahydro-1-benzazepine-7-sulfonyl chloride
• CAS: 927869-56-5
• 化学式: C₁₀H₁₀ClNO₃S
• mdl: MFCD11099485
• 分子量: 259.713
• InChiKey: QCHLNSXHASMIBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-氧代-2,3,4,5-四氢-1H-1-BENZ氮杂卓-7-磺酰氯 在 水 、 三乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 10.0h， 生成 4-((2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepine-7-sulfonamido)methyl)cyclohexanecarboxylic acid
  参考文献：
  名称：

  [EN] XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS
  [FR] DÉRIVÉS DE XANTHINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE BROMODOMAINES DE PROTÉINES BET

  摘要：

  本发明涉及一种具有以下通式(I)的化合物：(I)其中：- R为(C1-C6)烷基；- R''优选为 H；- Ar为(C5-C12)芳基；- X1为-C(=O)-或-SO2-；且- R'选自可能被取代的(C1-C6)烷基、杂芳基、(C5-C12)芳基及(杂)环烷基，或其药学上可接受的盐和/或互变异构体形式，或其消旋体、非对映异构体或对映异构体。

  公开号：

  WO2019086712A1
• 作为产物：
  描述：

  1,3,4,5-四氢-2H-1-苯并氮杂卓-2-酮 在 氯磺酸 作用下， 反应 20.0h， 以75%的产率得到2-氧代-2,3,4,5-四氢-1H-1-BENZ氮杂卓-7-磺酰氯
  参考文献：
  名称：

  [EN] XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS
  [FR] DÉRIVÉS DE XANTHINE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE BROMODOMAINES DE PROTÉINES BET

  摘要：

  本发明涉及一种具有以下通式(I)的化合物：(I)其中：- R为(C1-C6)烷基；- R''优选为 H；- Ar为(C5-C12)芳基；- X1为-C(=O)-或-SO2-；且- R'选自可能被取代的(C1-C6)烷基、杂芳基、(C5-C12)芳基及(杂)环烷基，或其药学上可接受的盐和/或互变异构体形式，或其消旋体、非对映异构体或对映异构体。

  公开号：

  WO2019086712A1

文献信息

• Integrated Strategy for Lead Optimization Based on Fragment Growing: The Diversity-Oriented-Target-Focused-Synthesis Approach
  作者：Laurent Hoffer、Yuliia V. Voitovich、Brigitt Raux、Kendall Carrasco、Christophe Muller、Aleksey Y. Fedorov、Carine Derviaux、Agnès Amouric、Stéphane Betzi、Dragos Horvath、Alexandre Varnek、Yves Collette、Sébastien Combes、Philippe Roche、Xavier Morelli

  DOI：10.1021/acs.jmedchem.8b00653

  日期：2018.7.12

  and fragment-based screenings. One major hurdle remaining in drug discovery is process automation of hit-to-lead (H2L) optimization. Here, we report a time- and cost-efficient integrated strategy for H2L optimization as well as a partially automated design of potent chemical probes consisting of a focused-chemical-library design and virtual screening coupled with robotic diversity-oriented de novo

  在过去的几十年中，高通量和基于片段的筛选技术的发展极大地促进了命中识别。药物发现中仍然存在的一大障碍是铅对铅（H2L）优化的过程自动化。在这里，我们报告了H2L优化的时间和成本有效的集成策略，以及强力化学探针的部分自动化设计，该技术包括集中化学库设计和虚拟筛选，以及面向机器人多样性的从头合成和自动化体外评估。虚拟库是通过组合一个激活的片段（与绑定到目标的子结构相对应）生成的，从计算机化学相关的一步有机转化清单中精心选择了使用计算机编码的化学反应进行功能化构建的集合。使用溴结构域抑制剂的优化作为测试案例证明了概念验证，从而验证了几种亲和力提高了几个数量级的化合物。
• Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
  申请人：Centre national de la recherche scientifique

  公开号：US11180510B2

  公开（公告）日：2021-11-23

  The present invention relates to a compound having the following formula (I): (I) wherein: —R is a (C1-C6)alkyl group; —R″ is preferably H; —Ar is a (C5-C12)arylene radical; —X1 is —C(═O)—or —SO2—; and —R′ is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.

  本发明涉及一种具有下式(I)的化合物：(I) 其中-R是(C1-C6)烷基；-R″最好是H；-Ar是(C5-C12)芳基；-X1是-C(═O)-或-SO2-；以及-R′选自可能取代的(C1-C6)烷基、杂芳基、(C5-C12)芳基和(杂)环烷基组成的组，或其药学上可接受的盐和/或同分异构体形式，或其外消旋体、非对映异构体或对映体。
• Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent <i>in Vivo</i> Pharmacodynamic Activity and Antitumor Efficacy
  作者：Shu-Yu Lin、Teng-Kuang Yeh、Ching-Chuan Kuo、Jen-Shin Song、Ming-Fu Cheng、Fang-Yu Liao、Min-Wu Chao、Han-Li Huang、Yi-Lin Chen、Chun-Yu Yang、Mine-Hsine Wu、Chia-Ling Hsieh、Wenchi Hsiao、Yi-Hui Peng、Jian-Sung Wu、Li-Mei Lin、Manwu Sun、Yu-Sheng Chao、Chuan Shih、Su-Ying Wu、Shiow-Lin Pan、Ming-Shiu Hung、Shau-Hua Ueng

  DOI：10.1021/acs.jmedchem.5b01640

  日期：2016.1.14

  Tryptophan metabolism has been recognized as an important mechanism in immune tolerance. Indoleamine 2,3-dioxygenase plays a key role in local tryptophan metabolism via the kynurenine pathway and has emerged as a therapeutic target for cancer immunotherapy. Our prior study identified phenyl benzenesulfonyl hydrazide 2 as a potent in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase. Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide 40, which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body weight loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg. Accordingly, 40, is proposed as a potential drug lead worthy of advanced preclinical evaluation.
• Synthesis of 7‐Sulfamoyl‐substituted 2‐Oxo‐2,3,4,5‐tetrahydro‐1<i>H</i>‐benzo[<i>b</i>]azepines
  作者：Mikhail V. Dorogov、Sergey A. Ivanovsky、Maria Y. Khakhina、Dmitry V. Kravchenko、Sergey E. Tkachenko、Alexandre V. Ivachtchenko

  DOI：10.1080/00397910600943493

  日期：2006.11.1

  Sulfochlorination of 2-oxo-2,3,4,5-tetrahydro-1H-benzo[b] azepine led to regioselective formation of the corresponding 7-chlorosulfonyl derivative. Starting from this reagent, a large number of substituted 2-oxo-7-sulfamoyl- 2,3,4,5-tetrahydro-1H-benzo[ b] azepines were obtained. This approach is amenable to combinatorial production of the title compounds, which possess promising therapeutic potential.
• 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase
  作者：Martin J. Walsh、Kyle R. Brimacombe、Henrike Veith、James M. Bougie、Thomas Daniel、William Leister、Lewis C. Cantley、William J. Israelsen、Matthew G. Vander Heiden、Min Shen、Douglas S. Auld、Craig J. Thomas、Matthew B. Boxer

  DOI：10.1016/j.bmcl.2011.08.114

  日期：2011.11

  Compared to normal differentiated cells, cancer cells have altered metabolic regulation to support biosynthesis and the expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important role in this anabolic metabolism. While the M1 isoform is a highly active enzyme, the alternatively spliced M2 variant is considerably less active and expressed in tumors. While the exact mechanism by which decreased pyruvate kinase activity contributes to anabolic metabolism remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may promote a metabolic program that is not conducive to cell proliferation. Here we report the third chemotype in a series of PKM2 activators based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships, selectivity and notable physiochemical properties are described. Published by Elsevier Ltd.